These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28562196)

  • 1. Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab.
    Jang S; Venna S
    J Oncol Pract; 2017 Jul; 13(7):462-464. PubMed ID: 28562196
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.
    Haug V; Behle V; Benoit S; Kneitz H; Schilling B; Goebeler M; Gesierich A
    Br J Dermatol; 2018 Oct; 179(4):993-994. PubMed ID: 29758087
    [No Abstract]   [Full Text] [Related]  

  • 3. Pembrolizumab as first line treatment of Merkel cell carcinoma patients - a case series of patients with various co-morbidities.
    Bystrup Boyles T; Schødt M; Hendel HW; Krarup-Hansen A; Junker N
    Acta Oncol; 2020 Jul; 59(7):793-796. PubMed ID: 32285728
    [No Abstract]   [Full Text] [Related]  

  • 4. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
    Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
    Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-PD1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature.
    Sellah D; Saint-Jean M; Peuvrel L; Khammari A; Quéreux G; Dréno B
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e159-e161. PubMed ID: 30451326
    [No Abstract]   [Full Text] [Related]  

  • 6. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
    Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
    Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma.
    Winkler JK; Bender C; Kratochwil C; Enk A; Hassel JC
    Br J Dermatol; 2017 Jan; 176(1):216-219. PubMed ID: 27038231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series.
    Xu MJ; Wu S; Daud AI; Yu SS; Yom SS
    J Immunother Cancer; 2018 May; 6(1):43. PubMed ID: 29848371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
    Tran DC; Colevas AD; Chang AL
    JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 12. Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab.
    Rogatsch M; Schmid J; Lax S; Uranitsch M; Schmid-Zalaudek K; Giuffrida R; Zalaudek I
    Eur J Cancer; 2018 Feb; 90():146-148. PubMed ID: 29237537
    [No Abstract]   [Full Text] [Related]  

  • 13. Pembrolizumab for classical Hodgkin's lymphoma.
    Burki TK
    Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
    [No Abstract]   [Full Text] [Related]  

  • 14. Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases.
    Knackstedt R; Sussman TA; McCahon L; Song JM; Funchain P; Gastman B
    Ann Oncol; 2019 Aug; 30(8):1399-1400. PubMed ID: 31250007
    [No Abstract]   [Full Text] [Related]  

  • 15. Deceleration in the rate of keratinocyte cancers and precancerous lesions during programmed death-1 inhibition therapy for advanced melanoma, with recrudescence on discontinuation.
    Roche L; Moriarty B; Fabre A; Crowne J; Lally A
    Clin Exp Dermatol; 2022 Mar; 47(3):582-584. PubMed ID: 34633688
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment.
    Bender C; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
    Ann Oncol; 2016 Jul; 27(7):1353-4. PubMed ID: 26951629
    [No Abstract]   [Full Text] [Related]  

  • 17. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
    Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
    Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In brief: Avelumab (Bavencio) for metastatic merkel cell carcinoma.
    Med Lett Drugs Ther; 2017 Jul; 59(1521):e120. PubMed ID: 28699934
    [No Abstract]   [Full Text] [Related]  

  • 19. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
    Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
    JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
    Fischer S; Hasan Ali O; Jochum W; Kluckert T; Flatz L; Siano M
    Oncol Res Treat; 2018; 41(6):391-394. PubMed ID: 29734143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.